New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study - HAL Accéder directement au contenu
Article dans une revue Rheumatology Année : 2022

New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study

Jean-Guillaume Letarouilly
Thao Pham
  • Fonction : Auteur
Émilie Acquacalda
  • Fonction : Auteur
Béatrice Banneville
  • Fonction : Auteur
Pauline Baudart
  • Fonction : Auteur
Élodie Bauer
  • Fonction : Auteur
Pascal Claudepierre
  • Fonction : Auteur
Arnaud Constantin
  • Fonction : Auteur
Emmanuelle Dernis
  • Fonction : Auteur
Renaud Felten
Philippe Gaudin
  • Fonction : Auteur
Bruno Gombert
  • Fonction : Auteur
Philippe Goupille
  • Fonction : Auteur
Xavier Guennoc
  • Fonction : Auteur
Isabelle Henry-Desailly
  • Fonction : Auteur
Denis Jullien
  • Fonction : Auteur
Elena Karimova
  • Fonction : Auteur
Sylvain Lanot
  • Fonction : Auteur
Loïc Le Dantec
  • Fonction : Auteur
Laurianne Plastaras
  • Fonction : Auteur
Nathalie Sultan
  • Fonction : Auteur
Xavier Truchet
  • Fonction : Auteur
Stéphane Varin
  • Fonction : Auteur
Daniel Wendling
Louise Gaboriau
  • Fonction : Auteur
René-Marc Flipo
  • Fonction : Auteur

Résumé

Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.
Loading...
Fichier non déposé

Dates et versions

hal-03979878, version 1 (09-02-2023)

Identifiants

Citer

Jean-Guillaume Letarouilly, Thao Pham, Adeline Pierache, Émilie Acquacalda, Béatrice Banneville, et al.. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study. Rheumatology, 2022, 61 (7), p.2848-2855. ⟨10.1093/rheumatology/keab819⟩. ⟨hal-03979878⟩
55 Consultations
0 Téléchargements
Dernière date de mise à jour le 26/06/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus